# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $15...
If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysi...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $15...
Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potentia...
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating...
Stifel analyst Dae Gon Ha initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Targ...